XOMA Corp
NASDAQ:XOMA
Intrinsic Value
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. [ Read More ]
The intrinsic value of one XOMA stock under the Base Case scenario is 16.46 USD. Compared to the current market price of 25.56 USD, XOMA Corp is Overvalued by 36%.
Valuation Backtest
XOMA Corp
Run backtest to discover the historical profit from buying and selling XOMA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
XOMA Corp
Current Assets | 169.3m |
Cash & Short-Term Investments | 153.5m |
Receivables | 15.2m |
Other Current Assets | 643k |
Non-Current Assets | 65m |
PP&E | 403k |
Other Non-Current Assets | 64.6m |
Current Liabilities | 19.5m |
Accounts Payable | 653k |
Accrued Liabilities | 2.8m |
Other Current Liabilities | 16m |
Non-Current Liabilities | 126.1m |
Long-Term Debt | 118.5m |
Other Non-Current Liabilities | 7.6m |
Earnings Waterfall
XOMA Corp
Revenue
|
4.8m
USD
|
Operating Expenses
|
-30.8m
USD
|
Operating Income
|
-26m
USD
|
Other Expenses
|
-20.3m
USD
|
Net Income
|
-46.3m
USD
|
Free Cash Flow Analysis
XOMA Corp
What is Free Cash Flow?
XOMA Profitability Score
Profitability Due Diligence
XOMA Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
XOMA Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
XOMA Solvency Score
Solvency Due Diligence
XOMA Corp's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
XOMA Corp's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XOMA Price Targets Summary
XOMA Corp
According to Wall Street analysts, the average 1-year price target for XOMA is 75.48 USD with a low forecast of 74.74 USD and a high forecast of 77.7 USD.
Ownership
XOMA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
XOMA Price
XOMA Corp
Average Annual Return | 27.36% |
Standard Deviation of Annual Returns | 74.38% |
Max Drawdown | -70% |
Market Capitalization | 293.8m USD |
Shares Outstanding | 11 635 000 |
Percentage of Shares Shorted | 3.45% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.
Contact
IPO
Employees
Officers
The intrinsic value of one XOMA stock under the Base Case scenario is 16.46 USD.
Compared to the current market price of 25.56 USD, XOMA Corp is Overvalued by 36%.